Studies on the usefulness of intranasal inactivated influenza vaccines

Vaccine

Volumn 28, Issue 38, 2010, Pages 6393-6397

  Tamura, Shin ichi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Inactivated vaccine; Influenza vaccine; Intranasal vaccine

Indexed keywords

CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CROSS REACTION; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, INNATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 77955654274     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.05.019     Document Type: Article

References (54)

1. Lamb R.A., Krug R.M. Orthomyxoviridae: the viruses and their replication. Fields virology 1996, 1353-1395. Lippincott-Raven Publishers, Philadelphia. B.N. Field, D.M. Knipe, P.M. Howley, R.M. Chanock (Eds.).
2. Murphy B.R., Webster R.G. Orthomyxoviruses. Fields virology 1996, 1397-1445. Lippincott-Raven Publishers, Philadelphia. B.N. Field, D.M. Knipe, P.M. Howley, R.M. Chanock (Eds.).
3. Schulman J.L., Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 1965, 89:170-174.
4. Webster G.G., Askonas B.A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 1980, 10:396-401.
5. Couch R.B., Kasel J.A. Immunity to influenza in man. Ann Rev Microbiol 1983, 37:529-549.
6. Murphy B.R., Clements M.L. The systemic and mucosal immune response of humans to influenza A virus. Curr Top Microbiol Immunol 1989, 146:107-116.
7. Murphy B.R. Mucosal immunity to viruses. Handbook of mucosal immunology 1994, 333-343. Academic Press, San Diego. P.L. Ogra, J. Mestecky, M.E. Lamm, W. Strober, J.R. McGhee, J. Bienenstock (Eds.).
8. McMichael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol 1994, 189:75-91.
9. Chen Z., Kurata T., Tamura S.-I. Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral protein. Jpn J Infect Dis 2000, 53:219-228.
10. Tamura S.-I., Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004, 57:236-247.
11. Tamura S.-I., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccine. Jpn J Infect Dis 2005, 58:195-207.
12. Maassab H.F. Adaptation and growth characteristics of influenza virus at 25°C. Nature (London) 1967, 213:612-614.
13. Waldman R.H., Wood S.H., Torres E.J., Small P.A. Influenza antibody response following aerosol administration of inactivated virus. Am J Epidemiol 1970, 91:574-585.
14. Wright P.F., Murphy B.R., Kervina M., Lawrence E.M., Phelan M.A., Karzon D.T. Secretory immunological response after intranasal inactivated influenza A virus vaccination: evidence for immunoglobulin A memory. Infect Immun 1983, 40:1092-1095.
15. Tamura S.-I., Samegai Y., Kurata H., Nagamine T., Aizawa C., Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988, 6:409-413.
16. Tamura S.-I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 1992, 22:477-481.
17. Tamura S.-I., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 1992, 149:981-988.
18. Tamura S.-I., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994, 12:419-426.
19. Tamura S.-I., Kurata T. Intranasal immunization with influenza vaccine. Mucosal vaccines 1996, 425-436. Academic Press, San Diego. H. Kiyono, P.L. Ogra, J.R. McGhee (Eds.).
20. Fassler R., Martin K., Forsberg E., Litzenburger T., Iglesias A. Knockout mice: how to make them and why. The immunological approach. Int. Arch. Allergy Immunol. 1995, 106:323-334.
21. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods 1997, 202:123-131.
22. Tamura S.-I., Iwasaki T., Thompson A.H., Asanuma H., Chen Z., Suzuki Y., et al. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol 1998, 79:291-299.
23. Yoshikawa T., Matsuo K., Matsuo K., Suzuki Y., Nomoto A., Tamura S.-I., et al. Total viral genome copies and virus-Ig complexes after infection with influenza virus in the nasal secretions of immunized mice. J Gen Virol 2004, 85:2339-2346.
24. Tamura S.-I., Funato H., Hirabayoshi Y., Kikuta K., Suzuki Y., Nagamine T., et al. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine 1990, 8:470-486.
25. Tamura S.-I., Funato H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., et al. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different haemagglutinin molecules. Eur J Immunol 1991, 21:1337-1344.
26. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Asanuma H., Sato Y., et al. Protection against influenza virus infection in poly Ig receptor-knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002, 168:2930-2938.
27. Watanabe I., Hagiwara Y., Yoshikawa T., Kiyono H., Takeda Y., McGhee J., et al. Immune responses against nasal adjuvant (CT112K)-combined influenza vaccine. Vaccine 2002, 20:3443-3455.
28. Ito R., Yoshikawa T., Ozaki Y., Hasegawa H., Suzuki Y., Aizawa C., et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia. Vaccine 2003, 21:2362-2371.
29. Shimada S., Kawaguchi-Miyashita M., Kushiro A., Sato T., Nanno M., Sako T., et al. Generation of polymeric immunoglobulin receptor-deficient mouse with marked reduction of secretory IgA. J Immunol 1999, 163:5367-5373.
30. Asahi-Ozaki Y., Yoshikawa T., Iwakura Y., Suzuki Y., Tamura S.-I., Kurata T., et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 2004, 74:328-335.
31. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers. Vaccine 1996, 14:113-119.
32. Hashigucci K., Tamura S.-I., Kurata T., Kamiya H., Ishidate T. Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers. Kansenshogaku Zasshi 1997, 71:153-161.
33. Tamura S.-I., Kurata T. Intranasal immunization for human application. Mucosal Immunol Update 1997, 5:8-10.
34. Tamura S.-I., Hasegawa H., Kurata T. Estimation of the effective doses of nasal-inactivated influenza vaccine in humans from mouse-model experiments. Jpn J Infect Dis 2010, 63:8-15.
35. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza a virus infection in mice. Vaccine 2003, 21:3212-3218.
36. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004, 101:5598-5603.
37. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reise S.C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
38. Kang S.M., Guo L., Yao Q., Skountzou I., Compans R.W. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 2004, 78:9624-9632.
39. Matsuo K., Yoshikawa T., Asanuma H., Iwasaki T., Hagiwara Y., Chen Z., et al. Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine 2000, 18:2713-2722.
40. Ichinohe T., Nagata N., Strong P., Tamura S., Takahashi H., Ninomiya A., et al. Prophylactic effects of chitin microparticles on highly pathogenic H5N1 influenza virus. J Med Virol 2007, 79:811-819.
41. Keitel W.A., Piedra P.A. Live cold-adapted, reassortant influenza vaccines (USA). Textbook of influenza 1998, 373-390. Blackwell Science, Oxford, [chapter 28]. K.G. Nicholson, R.G. Webster, A.J. Hay (Eds.).
42. CDC Recommendations of the ACIP: prevention and control of seasonal influenza with vaccines. MMWR 2009, 58(PR08):1-52.
43. Durrer P., Gluck U., Spyr C., Lang A.B., Zurbriggen R., Herzog C., et al. Mucosal antibody responses induced with a nasal virosome-based influenza vaccine. Vaccine 2003, 21:4328-4334.
44. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccines and the risk of Bell's palsy in Switzerland. New Engl J Med 2004, 350:896-903.
45. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
46. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochem Biophys Acta 2002, 1589:1-13.
47. Ichinohe T., Iwasaki A., Hasegawa H. Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev Vaccines 2008, 7:1435-1445.
48. Ichinohe T., Lee H.K., Ogura Y., Flavell R., Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 2009, 206:79-87.
49. Moldoveanu Z., Love-Homan L., Huang W.Q., Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosa immunization with influenza virus. Vaccine 1998, 16:1216-1224.
50. Hemmi H., Takeuchi O., Kawai T., Sato S., Sanjo H., Matsumoto M., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:656-660.
51. Abe T., Hemmi H., Moriishi K., Tamura S., Takaku H., Akira S., et al. Involvement of Toll-like receptor 9 signaling pathway in the induction of innate immunity by Baculovirus. J Virol 2005, 79:2847-2858.
52. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature 2001, 423:732-738.
53. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S.-I., et al. Synthetic double-stranded RNA [poly(I:C)]combined with mucosal vaccine protects against influenza virus infection. J Virol 2005, 79:2910-2919.
54. Ichinohe T., Tamura S.-I., Kawaguchi A., Ninomiya A., Imai M., Itamura S., et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated vaccine. J Infect Dis 2007, 196:1313-1320.